English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

De novo hepatitis B infection (HBV) occurs rarely after liver transplantion (LT) and is associated with severe hepatitis and graft loss. The liver grafts from anti-HBc positive donors are currently the main sources of de novo HBV infection after LT, which is usually defined by the development of positive HBsAg and/or detectable serum or liver HBV DNA in previously HBV naïve recipients. Here we reported the case of a liver transplant recipient with de novo HBV infection who had a favorable outcome after entecavir therapy. The patient received orthotopic liver transplantation because of end-stage cryptogenic cirrhosis and was found to have de novo HBV infection 6 months later. He was treated with entecavir and his serum HBV DNA turned undetectable 6 months later and HBsAg seroconversion was achieved 18 months later.

Entecavir Treatment is Safe and Highly Effective in the Patient with de Novo Hepatitis B Infection After Liver Transplantation: Case Report